Worth Remembering30 May 2019 13:07
That an update on NXP002 is imminent, its Fibrosis programme.
Today is the first day of true commercial validation of the Tech.
The £51M Ebers Deal was ahead of the curve but today’s confirmation of commercialisation for NXP100 is just the beginning.
Let the market digest what we have, I suspect we’ll get another update by the end of next week, & news is going to be pretty constant.
Any dips will be heavily bought into, there’s just too much going on here.